Home Biosimilar Antibodies Immunology & Inflammation Others Onvatilimab (Anti-B7-H5 / VISTA)
For research use only. Not for use in humans.

Onvatilimab (Anti-B7-H5 / VISTA)

Synonyms: VSIR， PD-1H

Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and bind to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumor activity. MW : 150 KD.

Onvatilimab (Anti-B7-H5 / VISTA)

Quality Control

Batch: A258202 Purity: 99% Protein concentration: 13.72mg/ml Endotoxin Level: ＜1EU/mg
99

Mechanism of Action

Description
Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and bind to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumor activity. MW : 150 KD.

Product Details

CAS No. 1969313-51-6
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07225075 RECRUITING Intracranial Aneurysm Balt USA 2026-02-04
NCT05957081 RECRUITING Drug: PMC-309 monotherapy|Drug: PMC-309 Dose Escalation in C Advanced or Metastatic Solid Tumors PharmAbcine 2024-01-03 PHASE1
NCT07754799 NOT_YET_RECRUITING Drug: Daunorubicin|Drug: Cytarabine|Drug: Liposome Mitoxantr Acute Myeloid Leukemia (AML) Institute of Hematology & Blood Diseases Hospital, China 2026-09-30 PHASE2
NCT05741853 RECRUITING Primary Progressive Aphasia; Dementia; Dementia, Frontotemporal; Alzheimer Disease; Neurodegenerative Diseases; Frontotemporal Lobar Degeneration; Apraxia, Motor; Dysarthria; Communication Disorders; Language Disorders; Speech Disorders; Neurocognitive Disorders; Aphasia; Bilingual Aphasia Stephanie Grasso 2023-05-01
NCT07200258 RECRUITING Gingival Recession Universidad Complutense de Madrid 2025-10-15
NCT07447206 NOT_YET_RECRUITING Drug: Angiotensin Receptor Blockers (ARBs)|Drug: Hydrophilic Hypertension; Hypercholesterolemia; Dementia Risk Factors University of Southern California 2026-05 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-07-17)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.